A tripartite collaboration will evaluate intranasal foralumab alongside anti-CD20 drugs in people with relapsing-remitting MS whose disease remains active despite B-cell–depleting treatment.
Tiziana Life Sciences, King Abdullah International Medical Research Center (KAIMRC), and the Foundation for Neurologic Diseases signed an MOU to support a clinical trial of intranasal foralumab in RRMS.
The trial will test foralumab as an add-on to anti-CD20 therapies for patients showing inadequate responses to those drugs alone.
Company CEO Ivor Elrifi framed the MOU as a step toward international collaboration in neuroimmunology and said the RRMS program will not change the blinded na-SPMS trial timeline, with results expected in October.
# What happened
Tiziana Life Sciences signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia and the U.S.-based Foundation for Neurologic Diseases to support a clinical trial testing intranasal foralumab in people with relapsing-remitting multiple sclerosis (RRMS).
# Who's involved
Tiziana CEO Ivor Elrifi is quoted in the company release describing the MOU as an important step toward international scientific collaboration in neuroimmunology and immunomodulation research.
# What the trial will test
The planned study will evaluate foralumab given intranasally as an add-on to anti-CD20 therapy in RRMS patients who continue to show disease activity despite anti-CD20 treatment. Anti-CD20 drugs cited in the report include Briumvi (ublituximab-xiiy), Kesimpta (ofatumumab), and Ocrevus (ocrelizumab).
# How foralumab is positioned
Foralumab is an antibody-based therapy delivered nasally in this program. Tiziana positions it as a modulator of T-cell and microglial activity rather than a B-cell–targeting agent. The company is pursuing multiple MS programs for foralumab: the RRMS add-on program described in the MOU and a separate program for non-active secondary progressive MS (na-SPMS).
Tiziana noted the RRMS program "represents an additional Multiple Sclerosis type beyond our ongoing non-active Secondary Progressive MS (na-SPMS) program," and said it will not affect the blinded Phase 2 na-SPMS trial, where dosing of the last patient was completed in June and results were expected in October.
# Why this matters for patients
Anti-CD20 therapies reduce relapse risk for many people with RRMS, but some patients still experience notable disease activity. For those patients, an add-on that targets different immune mechanisms could reduce inflammation that anti-CD20 treatment does not control. The MOU signals a coordinated effort to test that idea clinically.
# Immediate next steps and timelines
The announcement describes the MOU and that partners will support a planned clinical trial. The article does not provide trial design details, enrollment targets, start dates, or regulatory milestones for the RRMS study. Separately, the na-SPMS Phase 2 study (INFORM-MS, NCT06292923) remains blinded with results anticipated in October, according to Tiziana.
# Bottom line
Tiziana is moving forward with a collaborative clinical program to test intranasal foralumab as an add-on for RRMS patients who do not fully respond to anti-CD20 therapies. The collaboration brings international partners into the effort, and foralumab remains under evaluation in a separate na-SPMS trial that is blinded and nearing reported results.
The U.S. Food and Drug Administration (FDA) has given Abelzeta Pharma the go-ahead to launch an early-stage clinical trial to test its CAR T-cell therapy candidate for multiple sclerosis (MS) in people with hard-to-treat, progressive forms of the disease. According to Abelzeta, the study’s first part will enroll as man
Researchers in Germany have been granted more than $1 million to support the development of a novel skin patch designed to promote myelin repair in people with multiple sclerosis (MS) — funding that brings the experimental treatment closer to clinical testing, according to the team. The patch contains theophylline, a d
A new first-in-class treatment for Parkinson’s disease, designed to get past the brain’s protective barrier, was shown to be safe and well-tolerated in an early clinical trial, and to have “robust [central nervous system] exposure.” That’s according to new data from the Phase 1 trial, which involved both patients and h
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
There is some news from the MS Society https://www.mssociety.org.uk/research/latest-research/latest-research-news-and-blogs/alpha-lipoic-acid-moves-next-stage-octopus-trial Octopus is a multi arm multi stage (MAMS) adaptive trial with the aim of testing multiple drugs in phase II, then carry it forward into phase III a
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.